Sanofi has signed a memorandum of cooperation with the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Economic and Technological Development Zone to establish a new EUR 1 billion ($1.05 billion) insulin production base in China. 

The company’s investment will create a second Beijing production base to enhance local end-to-end insulin production and manufacturing capabilities. This will be Sanofi’s fourth production and supply base in China and represents the company’s single largest investment in China. 

The new production base in Beijing will add to Sanofi’s manufacturing network in China, which includes another Beijing production base that was expanded last year (2023) and production bases in Shenzhen and Hangzhou. 

Source: Sanofi